Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Metrics to compare | LAUL | Peers Peers - average of corresponding metrics from companies closely matching LAUL: DRREDDY, ALIVUS, HIKAL, AJANTPHARM, AUROPHARMA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLAULPeersSector |
---|---|---|---|---|
P/E Ratio | 163.8x | 20.6x | −0.5x | |
PEG Ratio | 25.14 | 0.70 | 0.00 | |
Price/Book | 7.9x | 2.8x | 2.6x | |
Price / LTM Sales | 6.2x | 2.7x | 3.0x | |
Upside (Analyst Target) | −18.2% | 28.8% | 57.1% | |
Fair Value Upside | Unlock | 15.4% | 10.6% | Unlock |